First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Clinical trial NCT00344773 · COMPLETED

Trial details

NCT number: NCT00344773
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Pulmonary Cancer

Start date: 2006-03-01
Primary completion: 2007-12-01
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.